Isatuximab is a CD38-targeting monoclonal antibody that exerts its anti-myeloma effects through multiple mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis. The gene discussed is CD38; the disease is plasma cell myeloma.